AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Other Events
Item 8.01 Other Events
On May3, 2017 and May5, 2017, respectively, the Company announced
the offering and the pricing of the Notes. Copies of these press
releases are attached as Exhibits 99.1 and 99.2, respectively,
hereto and incorporated herein by reference.
The legal opinion of Goodwin Procter LLP (including the consent
of Goodwin Procter LLP) (Exhibits 5.1 and 23.1 to this Current
Report on Form8-K) relating to the offering and sale of Notes is
filed with this Current Report on Form8-K.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
|
ExhibitNo. |
|
Description |
|
1.1 |
Underwriting Agreement, dated as of May4, 2017, among AMAG |
|
|
5.1 |
Opinion of Goodwin Procter LLP, counsel to the Company, |
|
|
23.1 |
Consent of Goodwin Procter LLP (included in Exhibit5.1) |
|
|
99.1 |
Press release, dated May3, 2017 |
|
|
99.2 |
Press release, dated May5, 2017 |
About AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth. AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG) Recent Trading Information
AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG) closed its last trading session down -0.55 at 18.55 with 2,275,779 shares trading hands.
